Tag: Vertess
In brief: SoCal’s new ‘powerful platform,’ Vertess’ recognition, WHILL’s growth
May 10, 2024HME News Staff
TUSTIN, Calif. – SG Homecare, a provider of HME and supplies, has acquired Western Drug Medical Supply, creating a platform to scale in Southern California.
The combined entity has more than $150 million in annual revenue and more than 500 employees.
"This is a transformative moment for both SG Homecare and Western Drug Medical Supply," said Jay Wendt, CEO, SG Homecare. "We're committed to a seamless integration, fostering a powerful platform for growth....
Vertess recognized for dealmaking
May 9, 2024HME News Staff
FORT WORTH, Texas – Vertess was recently named the No. 1 lower middle market investment bank for Q1 2024 by Axial, a private deal network serving professionals who own, advise and invest in North American companies. Vertess facilitated three transactions in the quarter:
MyDoc Urgent Care, a multi-location urgent care center based in Pennsylvania, was acquired by MyTown Health Partners, a comprehensive practice management services organization recently formed by Webster Equity...
In brief: Vivos picks Lincare, industry wins in GA, Belluscura tries DTC
October 27, 2023HME News Staff
LITTLETON, Colo. – Vivos Therapeutics, a medical technology company that makes oral appliances for patients suffering from mild-to-moderate obstructive sleep apnea and snoring in adults, has signed a distribution agreement with Lincare.
The agreement follows a successful a distribution pilot with Lincare and marks an important milestone in Vivos’ strategy to engage with leading durable medical equipment companies in the United States. Lincare will have a six-month exclusive deal...
Vertess announces pick up in M&A activity
October 26, 2023HME News Staff
FORTH WORTH, Texas – Vertess has closed five major health care transactions in the third quarter of 2023 with a total value of $75 million. The transactions were in various health care verticals. "At the end of 2022 and early 2023, we saw a sharp decline in the pace of M&A activity,” said Brad Smith, managing director. “We continued to push forward and remain patient. We are pleased for our clients that our perseverance with buyers resulted in several successes." Vertess sees signs...
M&A: Get your stories straight
March 29, 2023Theresa Flaherty, Managing Editor
DALLAS – While uncertainty in the broader economy has caused a slowdown in M&A, when buyers and sellers know what they want, deals are getting done, said experts at Medtrade on Tuesday.
“Why do you want to transact?” asked Brad Smith, managing director/partner at Vertess. “Why do you want to buy or sell? (If you’re selling), give a buyer enough information so they can make an educated decision. Make it a conversation. Have calls; get to know these people.”
Smith...
M&A analysts: ‘Focus on acquiring solid companies’
February 10, 2023Theresa Flaherty, Managing Editor
YARMOUTH, Maine – Industry analysts see steady deal-making in 2023, with a variety of companies making buys in both typically hot markets like respiratory and newly hot markets like repairs, but with more of a focus on due diligence.
“I think the interest is at both the national level, as well as the larger regionals, aggressively pursuing acquisitions,” said Pat Clifford, managing director, home medical equipment, for The Braff Group. “There is acquisition appetite...
In brief: Part B drug payments, Kalogon deal, new Vertess managing director
January 6, 2023HME News Staff
WASHINGTON – CMS should bolster its oversight of manufacturer-submitted average sales price (ASP) data to ensure accurate Part B drug payments, according to a new report from the Office of Inspector General.
Due to invalid or missing ASP data, CMS could not calculate an ASP-based payment amount for 8% of drug codes at least once between 2016-20, the OIG found.
“CMS was unable to calculate an ASP-based payment amount for several reasons, including that (1)...
Vertess taps former MSC Biomedical exec as new managing director
January 4, 2023HME News Staff
FORT WORTH, Texas – Vertess recently hired Jonathan Hadley as their newest managing director. Hadley has experience in the medical device space after leading and growing MSC Biomedical, a large medical device service organization in North America, where he served in various roles, including CEO. At MSC Biomedical, Hadley was able to work directly with medical device manufacturers, HME providers and former competitors as he executed upon a national network acquisition M+A strategy. "I have been...
Three make partner at Vertess
July 13, 2022HME News Staff
FORT WORTH, Texas – Vertess has promoted three managing directors to partner: Rachel Boynton, Anna Elliott and Robert Villalobos. Boynton joined VERTESS in 2018 as a managing director providing M&A advisory and consulting services to the intellectual and developmental disability (I/DD), behavioral health and related health care markets. Elliott, who joined the firm earlier this year, has experience in high-growth, health care technologies, including artificial intelligence and machine...
Choppy year ahead in M&A
June 24, 2022Theresa Flaherty, Managing Editor
Coming off a “crazy” year of dealmaking in 2021, the first quarter of 2022 was bound to be slower, driven in part by larger world issues like inflation and the war in Ukraine, says Brad Smith, managing director and partner at Vertess.
But deals are still getting done, as interest remains high in HME from both strategic players and institutional buyers, he said.
“There are fewer headwinds than previous years,” he said. “There’s more certainty and...